299 related articles for article (PubMed ID: 30270814)
1. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.
Swiatly A; Plewa S; Matysiak J; Kokot ZJ
J Ovarian Res; 2018 Oct; 11(1):88. PubMed ID: 30270814
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
3. Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery.
Swiatly A; Horala A; Matysiak J; Hajduk J; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30065196
[TBL] [Abstract][Full Text] [Related]
4. Mass Spectrometry-Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract][Full Text] [Related]
5. The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.
Carvalho VP; Grassi ML; Palma CS; Carrara HHA; Faça VM; Candido Dos Reis FJ; Poersch A
Transl Res; 2019 Apr; 206():71-90. PubMed ID: 30529050
[TBL] [Abstract][Full Text] [Related]
6. MASS SPECTROMETRY-BASED MITOCHONDRIAL PROTEOMICS IN HUMAN OVARIAN CANCERS.
Li N; Zhan X
Mass Spectrom Rev; 2020 Sep; 39(5-6):471-498. PubMed ID: 32020673
[TBL] [Abstract][Full Text] [Related]
7. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
8. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
Tchabo NE; Liel MS; Kohn EC
Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
[TBL] [Abstract][Full Text] [Related]
9. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
[TBL] [Abstract][Full Text] [Related]
11. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
[TBL] [Abstract][Full Text] [Related]
12. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
Jurisicova A; Jurisica I; Kislinger T
Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
[TBL] [Abstract][Full Text] [Related]
13. Clinical application of proteomics in ovarian cancer prevention and treatment.
Meani F; Pecorelli S; Liotta L; Petricoin EF
Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834
[TBL] [Abstract][Full Text] [Related]
14. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
15. Proteomics and biomarkers for ovarian cancer diagnosis.
Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
17. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.
Marzinke MA; Choi CH; Chen L; Shih IeM; Chan DW; Zhang H
Mol Cell Proteomics; 2013 Feb; 12(2):356-68. PubMed ID: 23172893
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]